FOCUS ON ORLISTAT - A NONSYSTEMIC INHIBITOR OF GASTROINTESTINAL LIPASE FOR WEIGHT-REDUCTION IN THE MANAGEMENT OF OBESITY

Orlistat, a gastric and pancreatic lipase inhibitor, is currently unde rgoing FDA review for the indication of weight reduction, In clinical trials, a significant weight loss of 5% to 10% has been demonstrated w ith orlistat dosages of 120 mg three times a day, for as long as 104 w eeks. Furthermore, modest reductions in cholesterol and LDL were obser ved. The drug was well tolerated, in trials, despite a high frequency of gastrointestinal side effects. Levels of vitamin A and F declined i n the short term, requiring vitamin supplementation in some patients. In preliminary data, a statistically significant increase in the risk of breast cancer has been observed; FDA approval is pending a review o f this safety information. In summary, orlistat is a well-tolerated ag ent with efficacy in the management of obesity, producing a significan t and sustained weight loss of up to 2 years.